From: BIOVECTRA
Date: Feb. 26, 2024
BIOVECTRA Partners on Canadian Solution to Establish a Domestic Supply Chain For Immunotherapies
BIOVECTRA is pleased to be part of a Canadian solution with our NGEN partners CCRM, Precision Nanosytems (Cytiva), Northern RNA, and OmniaBio to establish a Canadian supply chain network to accelerate and standardize lentiviral vector development from clinical to commercial manufacturing. Together we are building a next-generation immunotherapy manufacturing platform that will be used for new treatments to fight rare and difficult-to-treat diseases. Cell and Gene Therapies (CGT) are at the cutting-edge of patient care, tailored to the patient by reprograming targeted cells to stimulate their immune response to fight acquired and inherited diseases. CAR-T, CAR-NK-based therapies, the subject of this collaboration, are promising immunotherapies for cancer treatment.